|
1
|
Gill S, Loprinzi CL, Sargent DJ, et al:
Pooled analysis of fluorouracil-based adjuvant therapy for stage II
and III colon cancer: who benefits and by how much? J Clin Oncol.
22:1797–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Clinical Practice Guidelines in Colon
Cancer National Comprehensive Cancer Network. 2013
|
|
3
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti D: AJCC Cancer Staging Manual. Springer; New
York: 2010
|
|
4
|
Shi Q, Andre T, Grothey A, et al:
Comparison of outcomes after fluorouracil-based adjuvant therapy
for stages II and III colon cancer between 1978 to 1995 and 1996 to
2007: evidence of stage migration from the ACCENT database. J Clin
Oncol. 31:3656–3663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen L, Toyota M, Kondo Y, et al:
Integrated genetic and epigenetic analysis identifies three
different subclasses of colon cancer. Proc Natl Acad Sci USA.
104:18654–18659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kask K, Langel U and Bartfai T: Galanin -
a neuropeptide with inhibitory actions. Cell Mol Neurobiol.
15:653–673. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Branchek TA, Smith KE, Gerald C and Walker
MW: Galanin receptor subtypes. Trends Pharmacol Sci. 21:109–117.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Floren A, Land T and Langel U: Galanin
receptor subtypes and ligand binding. Neuropeptides. 34:331–337.
2000. View Article : Google Scholar
|
|
10
|
Misawa Y, Misawa K, Kanazawa T, et al:
Tumor suppressor activity and inactivation of galanin receptor type
2 by aberrant promoter methylation in head and neck cancer. Cancer.
120:205–213. 2014. View Article : Google Scholar
|
|
11
|
Rauch I and Kofler B: The galanin system
in cancer. EXS. 102:223–241. 2010.
|
|
12
|
Burleigh DE and Furness JB: Distribution
and actions of galanin and vasoactive intestinal peptide in the
human colon. Neuropeptides. 16:77–82. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng N, Kang T, Wen Y, Wong H, Walsh J and
Sachs G: Galanin inhibition of enterochromaffin-like cell function.
Gastroenterology. 115:330–339. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ahren B, Rorsman P and Berggren PO:
Galanin and the endocrine pancreas. FEBS Lett. 229:233–237. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Berger A, Santic R, Hauser-Kronberger C,
et al: Galanin and galanin receptors in human cancers.
Neuropeptides. 39:353–359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilaberte Y, Vera J, Coscojuela C, Roca
MJ, Parrado C and Gonzalez S: Expression of galanin in melanocytic
tumors. Actas Dermosifiliogr. 98:24–34. 2007.(In Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim KY, Kee MK, Chong SA and Nam MJ:
Galanin is up-regulated in colon adenocarcinoma. Cancer Epidemiol
Biomarkers Prev. 16:2373–2378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia CY, Yuan CX and Yuan CG: Galanin
inhibits the proliferation of glial olfactory ensheathing cells.
Neuropeptides. 39:453–459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berger A, Lang R, Moritz K, et al: Galanin
receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma
cells. Endocrinology. 145:500–507. 2004. View Article : Google Scholar
|
|
20
|
El-Salhy M: Effects of triple therapy with
octreotide, galanin and serotonin on a human colon cancer cell
line. Oncol Rep. 13:45–49. 2005.
|
|
21
|
Watanabe T, Itabashi M, Shimada Y, et al:
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. Int J Clin
Oncol. 17:1–29. 2012. View Article : Google Scholar
|
|
22
|
Fujiwara K, Ohuchida K, Mizumoto K, et al:
CD271+ subpopulation of pancreatic stellate cells
correlates with prognosis of pancreatic cancer and is regulated by
interaction with cancer cells. PLoS One. 7:e526822012. View Article : Google Scholar
|
|
23
|
Zhang L, Mizumoto K, Sato N, et al:
Quantitative determination of apoptotic death in cultured human
pancreatic cancer cells by propidium iodide and digitonin. Cancer
Lett. 142:129–137. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jorissen RN, Gibbs P, Christie M, et al:
Metastasis-associated gene expression changes predict poor outcomes
in patients with Dukes stage B and C colorectal cancer. Clin Cancer
Res. 15:7642–7651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smith JJ, Deane NG, Wu F, et al:
Experimentally derived metastasis gene expression profile predicts
recurrence and death in patients with colon cancer.
Gastroenterology. 138:958–968. 2010. View Article : Google Scholar
|
|
26
|
Mizuno H, Kitada K, Nakai K and Sarai A:
PrognoScan: a new database for meta-analysis of the prognostic
value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Holmes FE, Mahoney S, King VR, et al:
Targeted disruption of the galanin gene reduces the number of
sensory neurons and their regenerative capacity. Proc Natl Acad Sci
USA. 97:11563–11568. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O’Meara G, Coumis U, Ma SY, et al: Galanin
regulates the postnatal survival of a subset of basal forebrain
cholinergic neurons. Proc Natl Acad Sci USA. 97:11569–11574. 2000.
View Article : Google Scholar
|
|
29
|
Perel Y, Amrein L, Dobremez E, Rivel J,
Daniel JY and Landry M: Galanin and galanin receptor expression in
neuroblastic tumours: correlation with their differentiation
status. Br J Cancer. 86:117–122. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seufferlein T and Rozengurt E: Galanin,
neurotensin, and phorbol esters rapidly stimulate activation of
mitogen-activated protein kinase in small cell lung cancer cells.
Cancer Res. 56:5758–5764. 1996.PubMed/NCBI
|
|
31
|
Henson BS, Neubig RR, Jang I, et al:
Galanin receptor 1 has anti-proliferative effects in oral squamous
cell carcinoma. J Biol Chem. 280:22564–22571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trejter M, Brelinska R, Warchol JB, et al:
Effects of galanin on proliferation and apoptosis of immature rat
thymocytes. Int J Mol Med. 10:183–186. 2002.PubMed/NCBI
|
|
33
|
Kanazawa T, Iwashita T, Kommareddi P, et
al: Galanin and galanin receptor type 1 suppress proliferation in
squamous carcinoma cells: activation of the extracellular signal
regulated kinase pathway and induction of cyclin-dependent kinase
inhibitors. Oncogene. 26:5762–5771. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stevenson L, Allen WL, Turkington R, et
al: Identification of galanin and its receptor GalR1 as novel
determinants of resistance to chemotherapy and potential biomarkers
in colorectal cancer. Clin Cancer Res. 18:5412–5426. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Grade M, Hormann P, Becker S, et al: Gene
expression profiling reveals a massive, aneuploidy-dependent
transcriptional deregulation and distinct differences between lymph
node-negative and lymph node-positive colon carcinomas. Cancer Res.
67:41–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zeng X, Miura T, Luo Y, et al: Properties
of pluripotent human embryonic stem cells BG01 and BG02. Stem
Cells. 22:292–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anisimov SV, Tarasov KV, Tweedie D, Stern
MD, Wobus AM and Boheler KR: SAGE identification of gene
transcripts with profiles unique to pluripotent mouse R1 embryonic
stem cells. Genomics. 79:169–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
